Imbruvica ibrutinib: Clinical trial data

Data from 5 patients with high-risk, relapsed/refractory CLL who underwent prior allogeneic HSCT showed that salvage therapy with Imbruvica reduced lymph

Read the full 212 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE